Long-term outcome of maintenance infliximab therapy in children with Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 6, 2009, Pages 816-822

  Hyams, Jeffrey S ^a   Lerer, Trudy ^a   Griffiths, Anne ^b   Pfefferkorn, Marian ^c   Kugathasan, Subra ^d   Evans, Jonathan ^e   Otley, Anthony ^f   Carvalho, Ryan ^g   Mack, David ^h   Bousvaros, Athos ⁱ   Rosh, Joel ^j   Mamula, Petar ^k   Kay, Marsha ^l   Crandall, Wallace ^m   Oliva Hemker, Maria ⁿ   Keljo, David ^o   LeLeiko, Neal ^p   Markowitz, James ^q  

^a Farmington   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c RILEY HOSPITAL FOR CHILDREN   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e NEMOURS CHILDREN S CLINIC   (United States)

^f IWK HEALTH CENTRE   (Canada)

^g CHILDREN S MEDICAL CENTER   (United States)

^h CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁱ BOSTON CHILDREN S HOSPITAL   (United States)

^j MORRISTOWN MEMORIAL HOSPITAL   (United States)

^k CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁿ JOHNS HOPKINS HOSPITAL   (United States)

^o CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^p HASBRO CHILDREN'S HOSPITAL   (United States)

^q North Shore Long Island Jewish Health System ^*  (United States)

more..

Author keywords

Crohn's disease; Infliximab; Maintenance therapy; Pediatric Crohn's disease

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ANUS FISTULA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ARREST; HEART ARRHYTHMIA; HUMAN; INTESTINE RESECTION; LONG QT SYNDROME; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; COHORT STUDIES; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIERS ESTIMATE; MALE; REGISTRIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 67650234230     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20845     Document Type: Article

References (23)

1. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr. 2005;40:220-222.
2. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
6. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873.
7. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
8. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196.
9. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
10. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother. 2001;35:823-828.
11. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-838.
12. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104-111.
13. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther. 2003;18:425-431.
14. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr. 2004;39:46-52.
15. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4:1124-1129.
16. Wynands J, Belbouab R, Candon S, et al. 12-month follow-up after successful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46:293-298.
17. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030.
18. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
19. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416-421.
20. Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology. 1999;116:527-531.
21. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004;36:342-347.
22. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis. 2007;13:424-430.
23. de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353-358.